Newly Created Position Strategically Expands Development Capabilities
BOSTON, June 12, 2018 (GLOBE NEWSWIRE) — resTORbio, Inc. (NASDAQ:TORC) today announced that Kerry Russell, M.D., Ph.D., has joined the company as its Vice President of Clinical Development, a newly created position as part of the company’s effort to grow through strategic hires. In the role, Dr. Russell is responsible for the overall direction and execution of resTORbio’s expanding clinical program to advance new therapies for aging-related diseases such as respiratory tract infections and heart failure. resTORbio is a clinical-stage biopharmaceutical company targeting TORC1 and other biological pathways that regulate aging to develop innovative medicines with the potential to extend healthy lifespan.
“I am thrilled that someone of Kerry’s caliber has joined resTORbio to help us expand our clinical development capabilities. The addition of this role is driven by our expanding pipeline and the growing potential of our TORC1 inhibitor program,” said Joan Mannick, M.D., Co-founder and Chief Medical Officer of resTORbio. “Kerry not only brings extensive clinical development experience but also specialized expertise in cardiovascular medicine, which will be an important therapeutic area as we continue to uncover the potential benefits of TORC1 inhibition in heart failure and other diseases associated with the aging process.”
Dr. Russell joins resTORbio from Novartis where she was Director and Senior Translational Medicine Expert, Cardiovascular Division for Novartis Institutes for Biomedical Research. Previously, she was Associate Professor of Medicine, Section of Cardiovascular Medicine, Department of Internal Medicine, Yale School of Medicine. Prior, Dr. Russell completed her internship and residency at Yale-New Haven Hospital in New Haven, Conn., before moving on to complete a fellowship in cardiology at Yale School of Medicine. Dr. Russell earned a Bachelor’s degree in Biochemistry and Biology from Rice University, an M.D. from the University of Texas at Houston, and a Ph.D. from the University of Texas at Houston and MD Anderson Cancer Center. Her work has been recognized with numerous honors and recognitions. She currently serves as a reviewer for a number of prestigious scientific journals, including American Journal of Cardiology and Journal of Cell and Molecular Biology.
About TORC1 and RTB101
resTORbio’s approach focuses on the mechanistic target of rapamycin (mTOR) pathway, an evolutionary conserved pathway that regulates aging, and specifically on the selective inhibition of the target of rapamycin complex 1, or TORC1. TORC1 inhibition has been observed to prolong lifespan, enhance immune function, and delay or ameliorate multiple aging-related diseases including heart failure and neurodegenerative diseases in multiple animal studies across different species.
RTB101 is an orally administered small molecule that can be used alone or in combination with everolimus (an FDA-approved mTOR inhibitor) to selectively inhibit TORC1 without inhibiting TORC2. In the ongoing Phase 2b clinical trial, RTB101 is being evaluated alone and in combination with everolimus as an immunotherapy to decrease the incidence of respiratory tract infections in the elderly. Topline results from the ongoing Phase 2b trial are expected during the third quarter of 2018. The company expects to develop RTB101 for additional aging-related indications such as heart failure or neurodegenerative diseases.
resTORbio, Inc. is a clinical-stage biopharmaceutical company targeting TORC1 and other biological pathways that regulate aging to develop innovative medicines with the potential to extend healthy lifespan. resTORbio’s lead program is targeting the selective inhibition of TORC1, an evolutionary conserved pathway that contributes to the decline in function of multiple organ systems, including the immune, cardiac and neurologic systems.
Stern Investor Relations, Inc.